

SPECIAL TOPIX

Multi-Specialty Impact of COVID-19 (US)

Service Overview

Special Topix™: Multi-Specialty Impact of COVID-19 (US) is an ongoing series of monthly monitoring that evaluates the impact of COVID-19 on physicians and their practices – including, but not limited to, the utilization of telemedicine, at-risk patient groups, key concerns, support from industry, and future changes in prescribing patterns. Specialty reports are available for dermatology, gastroenterology, nephrology, neurology, and rheumatology.

Survey Details

Each report will consist of feedback gathered from 50 specialists geographically dispersed. A cross-specialty subscription is available upon request. Content categories include:

Demographics

- Patient volume, practice type, practice location, infusion capabilities, and clinical trial participation
- Nearby outbreak and related restrictions
- Personal travel to EU or China in past three months

Impact on practice

- Impact on practice
- Level of concern for patients
- Covering for partners
- Impact on clinical trial involvement
- Policies against travel/meetings
- Conference cancellations
- Restricting non-essential visits (industry, etc.)
- Implementation of telemedicine
- Preparedness for widespread local outbreak
- Appointment cancellations
- Rescheduling routine visits
- Overall impact to patient flow

Information on COVID-19

- Source(s) being used for your own information
- Most valuable information sources
- Contact with state health department
- How informed physicians feel about COVID-19 testing, guidelines, and treatment

Testing/screening

- Number requesting test
- Level of risk among requesting patients
- Number tested
- Number of positive/negative among those tested
- Logistics of testing
- Barriers to testing

Patients

- Percent at risk
- Characteristics of most at risk
- How well informed about true risks

Interaction with Industry

- Restrictions of in-person contact
- Recent industry contact methods
- Pharmaceutical industry support during outbreak
- Pharmaceutical company most active in addressing COVID-19 at national level / within personal practice

Opinions

- Overblown?
- Belief in being able to “flatten the curve”
- Satisfaction with how government handling
- Impact on supply chain for medication access
- Access to care from ER/ED or urgent care facilities
- Expected timeline for resolution?
- Government performance
- Willingness to try new products currently
- Willingness to initiate patients on therapy or change treatment
- Familiarity and anticipated utility of Gilead’s remdesivir against COVID-19
- Greatest concern related to COVID-19 (open end)

Specialty specific

- In immune, use of IL-6 inhibitors
- In MS, switching from or delaying next doses of immunosuppressant DMTs
- In migraine, use of newly approved therapy or anti-CGRP monoclonal antibodies
- In nephrology, impact in dialysis units